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The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant
epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood.
An open-label, randomized, parallel group, multicentre add-on study comparing gabapentin with lamotrigine in 109 patients
with drug-resistant localization-related epilepsy and learning disabilities was conducted: 39 patients were randomized to
gabapentin and 44 to lamotrigine. The study population had a range of learning disabilities and severe partial epilepsy.
The percentage of patients achieving a greater than or equal to 50% reduction in seizure frequency on gabapentin was
50%, (mean reduction in seizures was 51%). Compared to 48.6% of lamotrigine patients, no statistically significant treatment
differences could be identified. The safety profile of both drugs was consistent with that seen in previous clinical trials. Carer-
rated visual analogue scales detected significant improvements (P < 0.05) for the gabapentin-treated patients in seizure severity,
attention, general health and sleeping pattern, while for lamotrigine seizure severity improved significantly.
For learning disabled patients with resistant epilepsy, gabapentin and lamotrigine provide safe and effective treatment, with
positive benefits on behaviour.
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INTRODUCTION
Epilepsy is common amongst the learning disabled
population, especially those with severe or profound
degrees of learning disabilities1. The risk of develop-
ing a seizure disorder increases with the severity of
learning disability. Epilepsy occurring in people with
learning disabilities can be particularly difficult to treat
and assess. A large proportion of patients with learning
disabilities continue to have poorly controlled seizures
despite the use of two or more antiepileptic drugs
(AEDs)2. In addition, the common coexistence of be-
havioural and psychiatric disorders can lead to diffi-
culty in assessing treatment outcome, with such disor-
ders often being attributed to AED treatment. This has
lead to recommendations for the assessment of AEDs
to include behavioural measures3.
There have been few well conducted clinical stud-
ies investigating the impact of the newer generation of
antiepileptic drugs on seizure control and behaviour in
people with epilepsy and learning disabilities. There-
fore this trial, which involves a significant number of
patients with learning disabilities. Therefore this trial,
which involves a significant number of patients with
learning disabilities and epilepsy, is invaluable in pro-
viding real data to assist in the management of this
population. Both gabapentin (Neurontin) and lamot-
rigine (Lamictal) are newer generation AEDs first li-
censed in the early 1990s. Both are indicated for add-
on treatment of partial seizures with or without sec-
ondary generalization. Bhaumik et al. 19974, com-
pared both these AEDs along with vigabatrin as add-
on treatment in adults with learning disabilities and
epilepsy, in a small retrospective casenote study. The
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results of this analysis demonstrated that gabapentin
reduced seizure frequency by greater than 50% in 56%
of patients compared to 43% of patients taking lam-
otrigine. However firm conclusions cannot be drawn
from this study as it was not a direct prospective com-
parison and the sample size was too small.
The aim of this study was to evaluate the efficacy
and safety of gabapentin, together with its effects on
behaviour and mood, in a patient group with learning
disabilities whose epilepsy was uncontrolled on cur-
rent therapy, as part of a randomized controlled trial.
Lamotrigine was selected as the comparator drug.
MATERIALS AND METHODS
One hundred and nine learning disabled patients suf-
fering from refractory partial seizures with or with-
out secondary generalization, including a small num-
ber of patients who were entered with other seizure
types, were recruited into the study. This was a mul-
ticentre study conducted with 44 investigators from
the UK† . Permission for the study was obtained from
the local research ethics committees. Consent was ob-
tained either from the patient or from a patient’s rel-
ative, guardian or carer and an independent witness.
The study population comprised either outpatients or
inpatients of specialist hospitals, with an identified key
worker/carer who was available for the trial, able to
complete the carer rating scales, and to keep a record
of seizures.
Patients were eligible for the study if they were
aged 12 years and over, of either sex, and had a
localization-related epilepsy which was not satisfacto-
rily controlled by their existing antiepileptic medica-
tion5. In order to fulfil study criteria the subjects had
to be taking one, two or three standard AEDs (not in-
cluding gabapentin or lamotrigine) but still not achiev-
ing satisfactory seizure control. A minimum of four
seizures in each 28 day period and no seizure free 28
day period in the preceding 3 months was required for
entry. Patients had to have a degree of learning dis-
ability and to meet any level of the DSM-IV criteria
for mental retardation6.
The study exclusion criteria included individuals
who had had primary generalized seizures, symp-
tomatic generalized epilepsy or a history of non-
epileptic seizures. Concurrent therapy with antacids or
a recent participation in any clinical trial was not al-
lowed. Women were ineligible if they were pregnant or
lactating or of child-bearing potential and sexually ac-
tive and not practising a reliable method of contracep-
tion. A know hypersensitivity to gabapentin or lam-
otrigine, or significant renal or hepatic dysfunction,
also excluded enrolment. Patients on a stable dose of
monoamine oxidase inhibitors or antidepressants were
allowed to enter the study, providing that this medi-
cation was maintained at a constant dose throughout
the study. Intermittent use of benzodiazepines as res-
cue medication, for example rectal diazepam, was also
permitted.
Design
There was an initial baseline period of 8 weeks fol-
lowed by a titration period of up to 14 weeks. At visit
B1 a questionnaire was completed about the seizure
disorder in order to prevent patients with generalized
epilepsies from being randomized into the study. The
treatment was then evaluated for a minimum of 10
weeks (Fig. 1).
Medication was randomized in block sizes of six,
with each patient number being unique. Patient num-
bers were assigned sequentially and this determined
the treatment the patient would receive.
Dosing schedule
Patients were randomized to receive either gabapentin
or lamotrigine as add-on therapy to their existing AED
therapy (between one and three AEDs). The dosages
of the study drugs were increased over 14 weeks at
the investigator’s discretion to a maximum of 3600 mg
gabapentin (taken in three divided doses) and 400 mg
lamotrigine (taken in two divided doses). For patients
taking concurrent sodium valproate the lamotrigine
dose was 200 mg.
Assessments
Seizures were recorded in diaries and frequencies per
28 days calculated. The reduction in seizure frequency
between the baseline period and the last 8 weeks
of the treatment period was assessed using the R-
ratio (statistical transformation of the seizure frequen-
cies to provide normally distributed data). R-ratio =
(T − B)/(T + B) where T and B are the seizure
frequencies per 28 days during treatment and base-
line, respectively. Additionally, patients whose seizure
frequency was reduced by 50% or more were classi-
fied as responders. Patients whose seizure frequency
was reduced by less than 50% and those withdrawing
for treatment-related reasons were classified as non-
responders.
Mood, behaviour and dependency were assessed by:
† A complete list of all participating investigators is provided at the end of the paper.
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Baseline Period Titration Period Add-on Evaluation Period
gabapentin
lamotrigine
6 months
8 weeks Maximum 14 weeks Minimum 10 weeks 
Visits B1 B2 T2T1
Fig. 1: Schematic chart of study design.
(1) Key Carer-rated Visual Analogue Scales (de-
vised by Parke Davis).
(2) Crichton Royal Behavioural Rating Scale7.
(3) Whelan and Speake Rating Scale8.
(4) Physician’s Global Rating Scale (5 point scales)
(devised by Parke Davis).
The Key Carer Visual Analogue Scale (carer rating)
is used to assess carer outcome9. The Crichton Scale
covers relevant areas indicating functionality whereas
the Whelan and Speake Rating Scale assesses be-
havioural disturbance.
Safety
Safety and tolerability were assessed by adverse event
reports and by the number of patients withdrawing due
to adverse events. No laboratory assessments were re-
quired by the protocol to be carried out during the
study.
Statistical methodology
All patients randomized to a study treatment and who
took at least one dose of study medication were used in
the analysis. The frequency of seizures was compared
by analysis of variance of the R-ratio. The protocol as-
sumed a standard deviation of the R-ratio of 0.2526,
requiring 100 patients per treatment group to attain
80% power to detect a difference of 0.1 in the R-ratio
as a statistically significant difference (P ≤ 0.05).
As fewer than expected patients were recruited, 80%
power was achieved for detection of a slightly larger
difference of 0.15.
Responder rates for gabapentin and lamotrigine
were compared using logistic regression. Group differ-
ences in the Key Carer Visual Analogue Scales were
assessed using two-sampled t-tests, and changes from
baseline were assessed using paired t-tests. Individual
aspects and total scores from the Whelan and Speake
Rating Scale and Crichton Scale were assessed non-
parametrically using the Wilcoxon rank sum test, and
the Wilcoxon signed rank test.
All statistical tests were two-sided (P < 0.05). In
considering the significance of all tests carried out
on the behavioural and carer rating scales, no adjust-
ment was made for multiple comparisons. Thus, re-
sults which are borderline significant at 5% have to
be treated with caution, as not all the tests are inde-
pendent and some significant results could have arisen
purely by chance due to the number of scales assessed.
RESULTS
Patient population
A total of 109 learning disabled patients were re-
cruited from 44 sites, 83 of which were randomized
to treatment (Fig. 2). Thirty-nine patients entered the
titration phase on gabapentin, and 44 on lamotrigine.
No patients withdrew during the baseline period of
8 weeks. Thirty-four patients completed the trial in
the gabapentin group, and there were 35 completers
on lamotrigine. Some patients had been misclassi-
fied based on inaccurate information during baseline.
These patients were included in all the efficacy analy-
ses. Patient characteristics are shown in Table 1, with
a summary of the seizure types in Table 2.
Thirty-five patients were evaluated on gabapentin
after visit T1, while 38 patients entered the evaluation
phase on lamotrigine.
The mean dose of gabapentin during the evaluation
phase was 1749 ± 35 mg per day (minimum 400 mg
per day, maximum 3600 mg per day). The mean dose
for lamotrigine was 207 ± 38 mg per day (minimum
25 mg per day, maximum 400 mg per day).
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The most frequently used concurrent antiepilep-
tic medications were carbamazepine and sodium val-
proate, taken by 69.9% and 65.1% of trial patients,
respectively. In addition, a further nine other AEDs
were taken concurrently, diazepam (13.3%) pheny-
toin (12%), clonazepam (10.8%), vigabatrin (7.2%),
phenobarbitone (6%), clobazam (3.6%), ethosuximide
(2.4%), topiramate (1.2%) and primidone (1.2%). The
number of AEDs started before enrolment for each
treatment group were very similar, in both groups the
majority of patients had taken two AEDs (41% and
50% in the gabapentin and lamotrigine groups, respec-
tively), with approximately the same numbers taking
one or three.
Table 1: Patient characteristics.
Treated patients Baseline withdrawals
Gabapentin Lamotrigine N = 26
N = 39 N = 44
Sex, No. (%)
Men 24 (61.5) 29 (65.9) 13 (50.0)
Women 15 (38.5) 15 (34.1) 13 (50.0)
Age, Year
Mean (SD) 38 (11.1) 33 (11.5) 36 (14.8)
Range 16–59 15–57 15–67
Table 2: Seizure types by treatment group.
Seizure type Gabapentin Lamotrigine
N = 39 N = 44
Simple partial 7 (9%) 9 (13%)
Complex partial 39 (49%) 29 (43%)
Secondary generalized 27 (34%) 25 (37%)
Absence 2 (3%) 1 (2%)
Tonic 0 1 (2%)
Other 4 (5%) 2 (3%)
The study population were all identified as having a
learning disability, in addition, the following problems
with adaptive functioning were seen. In terms of mo-
bility, 39% of those randomized were either unable to
walk, or were only capable of walking with supervi-
sion. When considering aspects of dressing and feed-
ing, 72% were unable to dress adequately without a
degree of supervision and 59% required a degree of
supervision for adequate feeding. The details recorded
for each patient at the beginning of the trial also re-
vealed that 30% of those recruited were unable to talk.
The carer ratings by their nature provide a key in-
sight into the dependency of these patients and the de-
gree of supervision that they require. Carer assessment
of need for assistance was high, with general attention
tending towards poor. Assessment of seizure severity
was also high with 59% of the study population con-
sidered to experience seizures nearer to severe than
mild.
The disabled population recruited into the trial all
had epilepsy to varying degrees, median monthly base-
line seizure frequency for randomized patients was 13,
ranging from 1 to 796.
Efficacy
Seizure control
The percentage of patients achieving a greater than
or equal to 50% reduction in seizure frequency
on gabapentin was 50%, with a mean reduction in
seizures over the course of the study of 51%. Com-
pared to lamotrigine, no statistically significant treat-
ment differences could be identified (48.6% of patients
on lamotrigine achieved a greater than 50% reduc-
tion in seizure frequency and the mean reduction in
seizures were identical).
Three patients (7.7%) on gabapentin and five
patients (11.4%) on lamotrigine were seizure free dur-
ing the evaluation phase. Only one patient was seizure
free during the titration period (in the lamotrigine
group).
Analysis of the R-ratio (seen in Table 3) also
demonstrates that gabapentin and lamotrigine
achieved equivalent efficacy.
Behaviour
The carer and behavioural scales overall showed im-
provements in both groups. The measures achieving
statistical significance compared to baseline are out-
lined in Fig. 3. Despite the high number of behavioural
measures assessed, relatively few showed statistically
significant differences between treatments, those that
did favoured gabapentin (Fig. 3).
Key Carer/Worker Visual Analogue Scale. The re-
sults from the carer ratings were evaluated using the
100 mm visual analogue scales and were tested para-
metrically using t-tests. No statistically significant dif-
ferences were detected when comparing treatments.
Most scales showed an improvement from baseline
(i.e. within-group analysis) with treatment. This im-
provement was statistically significant (P < 0.05,
paired t-test) in the following scales: seizure sever-
ity, attention, general health and sleeping pattern im-
proved on gabapentin, whilst only seizure severity im-
proved significantly amongst patients on lamotrigine.
Crichton Royal Behavioural Rating Scale. The re-
sults showed a significantly greater improvement on
gabapentin than on lamotrigine (P < 0.05) in the
measurement of co-operation, communication and
restlessness. Total score also improved significantly
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Fig. 2: Patient recruitment and withdrawals.
Significant improvement Significant improvement Significant differences
on gabapentin on lamotrigine between treatments
Key Carer Rating Seizure severity Seizure severity
Scale Sleeping pattern
Attention
General health
Crichton Royal Co-operation Communication∗
Behaviour Rating Restlessness Co-operation∗
Scale Restless∗
Physician’s Rating Seizure severity Challenging behaviour
Scale General health General health
∗ In favour of gabapentin.
Fig. 3: Synopsis of statistically significant improvements on individual items of behavioural rating scales.
(P = 0.01) in the gabapentin group but not in lam-
otrigine patients.
Challenging Behaviour (Whelan and Speake).
Gabapentin was similar to lamotrigine on this scale,
and both drugs reduced the level of challenging be-
haviour as a total score over the duration of the trial.
Physician’s Global Rating Scale. The Physician’s
Global Rating Scale showed statistically significant
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Table 3: Results for total seizures.
Variable Gabapentin Lamotrigine
Total number of seizures SD N SD N
(standardized 28 day period)
Median (SD) baseline 15.1 (24.9) 39 11.8 (123.2) 42
Median (SD) titration 6.0 (27.0) 34 6.9 (64.9) 38
Median (SD) maintenance 4.7 (40.0) 33 5.0 (52.1) 33
% patients with 50%
reduction in frequency 50.0 48.6
N = 17 17
95% CI for difference (−22.2, 25.0)
R-ratio Mean (SD) −0.37 (0.38) 33 −0.37 (0.49) 32
95% CI of difference (−0.242, 0.234)
% reduction in seizure
frequency 50.6 50.8
Mean
improvements over baseline (P < 0.01) for challeng-
ing behaviour, seizure severity and general health for
both treatment groups at both visits T1 and T2, with
the exception of general health in the gabapentin group
at T1. However, there was an improvement in general
health by T2 from gabapentin with a P-value < 0.01.
Adverse events
The overall incidence of adverse events was similar in
both treatment groups (62% in gabapentin and 50% in
lamotrigine—Table 4). Approximately 10% reported
serious adverse events on gabapentin and 11% on lam-
otrigine.
Table 4: Overview of adverse events.
Gabapentin Lamotrigine
Number (%) of patients with adverse
events
All adverse events 24 (62%) 22 (50%)
Drug-associated adverse events 13 (33%) 11 (25%)
Number of deaths 1 0
Number (%) patients with serious 4 (10%) 5 (11%)
Adverse events
Number (%) of patients withdrawn 3 (8%) 4 (9%)
due to adverse events
Almost twice as many reports were made for
gabapentin than for lamotrigine; these can be at-
tributable to some degree to somnolence. Somnolence
was experienced by nine patients (23%) during titra-
tion, and ataxia by four patients (10%) on gabapentin.
However, during the evaluation phase only one in-
stance of somnolence was reported on gabapentin,
suggesting that the incidence was restricted to dose
titration and resolved after dose stabilization.
During the evaluation phase, the most commonly
occurring adverse event was convulsions two patients,
one in each treatment group). Not one adverse
event was experienced by more than one patient on
gabapentin, however, two patients reported cases of
respiratory infection on lamotrigine and a further two
reported urinary tract infections.
One patient died during this study while being
treated with gabapentin. He had two myocardial in-
fractions before the end of titration. The investigator
considered these events to be severe in intensity and
unlikely to be related to the study drug.
Four patients experienced serious adverse events on
gabapentin, while five suffered serious adverse events
on lamotrigine. Only one patient experienced a serious
adverse event related to treatment. This patient was in
the gabapentin group and suffered drowsiness.
Seven patients were withdrawn due to adverse
events: three patients in the gabapentin group (8%) and
four in the lamotrigine group (9%). One withdrawal
on gabapentin due to an adverse event (of vomiting)
was considered (probably) related to study drug. Three
patients in the lamotrigine group were withdrawn due
to related adverse events. Two patients suffered rash
and peripheral oedema. The third patient had a rash.
DISCUSSION
This is the first reported randomized trial of an add-on
AED in a defined population of individuals with severe
epilepsy and learning disability. The results are impor-
tant and act against a therapeutic nihilism. The study
also shows both study drugs to be effective and to have
an impact on behaviour. Some differences could be
observed between the two AEDs, with more positive
differences in behavioural outcomes observed on ad-
dition of gabapentin.
The number of patients recruited into the study was
lower than anticipated. The difficulties encountered
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were primarily due to problems associated with en-
rolling patients with learning disabilities into a clin-
ical trial. Due to the nature of their condition, many
patients are unable to co-operate with study proce-
dures themselves, hence successful recruitment lies
in the ability to identify a key carer to complete as-
sessments on the patient’s behalf. Many patients were
excluded from randomization because, on reviewing
their seizure history and descriptions, it was felt that
it was more likely that they had a generalized rather
than a localization-related epilepsy. The original sam-
ple size estimation stated in the protocol that 100
patients treatment group would be required in order
to give sufficient power to detect a difference of 0.1
in the R-ratio as a primary end-point. Despite recruit-
ment not meeting this initial target, the patient num-
bers enrolled still provided a good sample size for
the adult learning disabled. No previous parallel group
randomized studies in learning disabled adults with
epilepsy could be identified, however, there have been
three other randomized, controlled trials in Lennox–
Gastaut syndrome10–12. These Lennox–Gastaut stud-
ies have provided important data, but with more spe-
cific, special populations, many in childhood and spe-
cific to Lennox–Gastaut syndrome.
Thirty-four patients completed the gabapentin eval-
uation phase (87.2%) and 35 patients (79.5%) patients
completed the lamotrigine evaluation phase. We can
thus conclude that the majority of patients tolerated
both drugs adequately.
Seizure severity
Overall the analysis of seizure frequency demon-
strated that gabapentin showed no differences in the
primary efficacy end-point compared to lamotrigine,
however, as the sample size was lower than antici-
pated, it is not possible to statistically state equiv-
alence in terms of efficacy for the two antiepileptic
drugs.
The results of the carer rating scale analysis for
patients on gabapentin produced a statistically signif-
icant positive effect on improving seizure severity, as
did the physician’s rating scale. The carer rating evi-
denced improvements in seizure severity for patients
on lamotrigine.
Behaviours
Although seizure diaries have become the most widely
used assessment measure in clinical practice, simple
counts of seizures may not be the only, or the most
useful, measure of outcome, even if such diaries could
be relied upon to be accurate13. Carers of people
with learning disabilities are also the most frequent
observers, and typically present a range of concerns
about epilepsy which extends beyond the number of
seizure events. Therefore, systematic elucidation and
measurement of these concerns are important since the
reduction may be likely to represent significant clini-
cal improvement. This study set out to identify var-
ious other useful measures of clinical improvement
in this patient group using a variety of rating scales,
arguably the most useful of which was the carer rat-
ing. This involved each carer completing a visual ana-
logue scale encompassing the following factors: ac-
tivity level, tiredness, self-care skills, sleeping pattern,
mood, challenging behaviour, general health, attention
and seizure severity.
General health and sleeping pattern
Significant improvements in general health were
recorded in the physician’s rating scale for both
gabapentin and lamotrigine. In the gabapentin group
this finding was supported by the positive effect
recorded on both general health and sleeping pattern
in the key carer rating scale analysis.
Disruptive behaviour—co-operation,
restlessness and attention span
Disruptive behaviour can be particularly distressing
and tiresome for family and carers of patients with
learning disabilities. People with learning disability
and refractory epilepsy may be more prone to be-
havioural problems14. Refractory epilepsy can rep-
resent more serious underlying brain pathology pre-
disposing the person to behavioural problems15. Be-
havioural consequences of epilepsy and its treatment
may be difficult to disentangle16. Agitation and gen-
eral social disruption throughout the day are common
problems. Therefore, effective AED treatment, as well
as controlling seizures, should also have a beneficial
effect on cognitive function and overall patient be-
haviour.
The variety of scales used in assessing these patients
and the analysis of individual elements of these scales
may be expected to result in a few significant improve-
ments or deteriorations occurring by chance alone.
However, far more significant changes, all of which
were improvements, were detected than would be ex-
pected due to chance.
Gabapentin showed an improvement in co-operation
and restlessness from the CRBRS baseline measures.
In addition, the total score change from baseline to
treatment end was improved for the gabapentin group
but not for lamotrigine. There were significant differ-
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ences between the two treatments on measures of co-
operation, communication and restlessness for the CR-
BRS. No negative changes were detected in the Whe-
lan and Speake scale designed to assess aberrant be-
haviour in the learning disabled. Both gabapentin and
lamotrigine reduced the level of challenging behaviour
as a total score over the duration of the trial.
The investigator’s (physician’s) rating demonstrated
a significant improvement over baseline in challeng-
ing behaviour as well as seizure severity and general
health scores, suggesting an overall positive feeling
from the physicians involved.
The results from this trial demonstrate that
gabapentin and lamotrigine do not exacerbate any of
the challenging behaviours observed in this patient
population. This has implications for physicians in-
volved in the clinical management of learning disabled
patients suffering with epilepsy. Gabapentin and lam-
otrigine both provide an effective antiepileptic treat-
ment, proven to positively influence seizure severity,
whilst not worsening any other parameters (such as
challenging behaviour), and with their proven safety
profile, are unlikely to induce any other problems.
Adverse events
The adverse events noted for both drugs are simi-
lar to those of previous reviews and those outlined
in their respective product characteristics summaries.
Both drugs have consistently demonstrated excellent
tolerability, this is supported further in learning dis-
abled patients by the results of this trial.
The number of patients with adverse events consid-
ered associated to treatment by the investigator was
33% in the gabapentin group and 25% in the lamotrig-
ine group.
Somnolence and ataxia associated with gabapentin
treatment was reported by 28% of patients during the
titration phase, however, during the evaluation phase
only one instance of somnolence was reported. This il-
lustrates that the majority of these adverse events seen
with gabapentin abate once the dose is stabilized (Ta-
ble 5).
Table 5: Total numbers of adverse events during titration
evaluation (P = 0.11).
Gabapentin Lamotrigine
No. (%) of patients with adverse 24 (62%) 19 (43%)
events during titration
No. of reports during titration 53 31
No. (%) of patients with adverse 4 (11%) 10 (26%)
events during evaluation
No. of reports during evaluation 7 14
The number of patients withdrawing from the study
due to adverse events was particularly modest for this
patient group. Only seven patients withdrew (three in
the gabapentin and four in the lamotrigine group).
CONCLUSIONS
The reductions in seizure frequency observed in this
study prove that both gabapentin and lamotrigine are
effective AEDs for patients with epilepsy and learning
disabilities. Improvements in seizure control were the
same for both treatment groups.
The safety profiles of gabapentin and lamotrigine
were consistent with those seen in previous trials pro-
viding further evidence to confirm the good tolera-
bility of both of these drugs in a patient population
that is often described as prone to drug-related adverse
events. Side effects with gabapentin were mainly con-
fined to the titration phase, and once the maintenance
dose was reached, fewer problems were seen.
Behavioural rating scales suggest improvements
in co-operation, communication and restlessness for
patients on gabapentin when compared to lamotrig-
ine. With both drugs a number of other positive be-
havioural trends were noted from baseline.
Gabapentin and lamotrigine both provide effective
antiepileptic treatment, proven to positively influence
seizure severity, whilst not worsening any other pa-
rameters (such as challenging behaviour), and with
their proven safety profile, are unlikely to induce any
other problems.
This study has shown the positive impact of AEDs
on a difficult to control population.
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